Champion M C, Hartnett M, Yen M
CMAJ. 1986 Sep 1;135(5):457-61.
Domperidone is a dopamine antagonist that has recently been released in Canada. Unlike metoclopramide hydrochloride, the other available dopamine antagonist, it does not readily enter the central nervous system. Domperidone acts as both an antiemetic and an upper gastrointestinal tract prokinetic agent. It is rapidly absorbed after oral administration, and few side effects have been reported. Domperidone has been approved for use in Canada for the symptomatic management of upper gastrointestinal tract motility disorders and to prevent gastrointestinal symptoms associated with the use of dopamine agonist agents in Parkinson's disease. The pharmacologic features, indications and side effects of domperidone are reviewed.
多潘立酮是一种多巴胺拮抗剂，最近在加拿大上市。与另一种可用的多巴胺拮抗剂盐酸甲氧氯普胺不同，它不易进入中枢神经系统。多潘立酮兼具止吐药和上消化道促动力药的作用。口服后吸收迅速，且报道的副作用较少。多潘立酮已在加拿大获批用于上消化道动力障碍的症状性治疗，以及预防帕金森病中使用多巴胺激动剂所致的胃肠道症状。本文对多潘立酮的药理特性、适应证及副作用进行综述。
